-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Atrium Therapeutics, Lowers Price Target to $20

Benzinga·10/28/2026 11:42:13
Listen to the news
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Atrium Therapeutics (NASDAQ:RNA) with a Buy and lowers the price target from $25 to $20.